Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 21
Encontrada(s) 1 página(s)

e-Archivo. Repositorio Institucional de la Universidad Carlos III de Madrid
Publicación Artículo científico (JournalArticle)

Terapias avanzadas en enfermedades raras, Advanced therapies for rare diseases, Advanced therapies for rare diseases

  • Fillat, Cristina
  • Río Nechaevsky, Marcela del
  • Martínez Santamaría, Lucía
  • Bueren, Juan A.
Las terapias avanzadas comprenden un grupo de medicamentos biológicos basados en la terapia génica, la terapia celular y la ingeniería de tejidos. En este artículo se presentan algunos conceptos básicos, se describen las estrategias más prometedoras y se detallan los resultados de diferentes ensayos clínicos para un grupo significativo de enfermedades, especialmente las enfermedades hereditarias monogénicas. Se hace un mayor hincapié en la terapia génica ex vivo en enfermedades del sistema hematopoyético, al ser el grupo de enfermedades pioneras que además han orientado la investigación en el campo. Destacamos también algunos ejemplos de éxito de terapia génica in vivo y señalamos la contribución de la terapia celular y de la ingeniería de tejidos al grupo de enfermedades raras de la piel. Pretendemos con ello dar una visión de la situación de las terapias avanzadas en enfermedades raras y señalamos algunas de las vías de futuro orientadas al desarrollo de tratamientos más eficaces y seguros., Advanced therapies are a group of medicines for human use based on gene therapy, somatic cell therapy or tissue-engineering. In this paper we present some general basic concepts, describe the most promising strategies and summarize the results of a variety of clinical trials for a significant group of monogenic inherited diseases. Major emphasis is placed on ex vivo gene therapy approaches for diseases of the hematopoietic system, since these corresponded to pioneering treatments that have guided research in this field. We also highlight some examples of successful in vivo gene therapy and point out the contribution of somatic cell therapy and tissue engineering to the group of rare skin diseases. We aim to provide an overview of the state of the art of advanced therapies in rare diseases and highlight some of the cutting-edge technologies under development that can provide more effective and safer treatments in the future., Los laboratorios de los autores están financiados por: Laboratorio IDIBAPS/CIBERER, Ministerio de Eco-nomía y Competitividad (BIO2014-57716-C2-2-R), Instituto de Salud Carlos III (IIS10/00014), Generalitat de Catalunya (SGR14/248), Fondation Jerome Lejeu-ne (FJL14). El trabajo realizado por el grupo del CIE-MAT/CIBERER/IIS Fundación Jiménez Díaz (UAM) está financiado por la Comisión Europea (FP7 HEALTH-F5-2012-305421, EUROFANCOLEN), Ministerio de Economía y Competitividad (SAF2012-39834), Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III (RETICS RD12/0019/0023; PI08/0701), y Dirección General de Investigación de la Comunidad de Madrid (CellCAM; Ref S2010/BMD-2420).
Repisalud
Publicación Artículo científico (JournalArticle)

Decapping protein EDC4 regulates DNA repair and phenocopies BRCA1

  • Hernández, Gonzalo
  • Ramírez, María José
  • Minguillón, Jordi
  • Quiles, Paco
  • Ruiz de Garibay, Gorka
  • Aza-Carmona, Miriam
  • Bogliolo, Massimo
  • Pujol, Roser
  • Prados-Carvajal, Rosario
  • Fernández, Juana
  • García, Nadia
  • López, Adrià
  • Gutiérrez-Enríquez, Sara
  • Diez, Orland
  • Benitez, Javier
  • Salinas, Mónica
  • Teulé, Alex
  • Brunet, Joan
  • Radice, Paolo
  • Peterlongo, Paolo
  • Schindler, Detlev
  • Huertas, Pablo
  • Puente, Xose S
  • Lázaro, Conxi
  • Pujana, Miguel Angel
  • Surrallés, Jordi
BRCA1 is a tumor suppressor that regulates DNA repair by homologous recombination. Germline mutations in BRCA1 are associated with increased risk of breast and ovarian cancer and BRCA1 deficient tumors are exquisitely sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors. Therefore, uncovering additional components of this DNA repair pathway is of extreme importance for further understanding cancer development and therapeutic vulnerabilities. Here, we identify EDC4, a known component of processing-bodies and regulator of mRNA decapping, as a member of the BRCA1-BRIP1-TOPBP1 complex. EDC4 plays a key role in homologous recombination by stimulating end resection at double-strand breaks. EDC4 deficiency leads to genome instability and hypersensitivity to DNA interstrand cross-linking drugs and PARP inhibitors. Lack-of-function mutations in EDC4 were detected in BRCA1/2-mutation-negative breast cancer cases, suggesting a role in breast cancer susceptibility. Collectively, this study recognizes EDC4 with a dual role in decapping and DNA repair whose inactivation phenocopies BRCA1 deficiency.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Global proteomic and methylome analysis in human induced pluripotent stem cells reveals overexpression of a human TLR3 affecting proper innate immune response signaling

  • Requena Osete, Jordi
  • Álvarez Palomo, Ana Belén
  • Codina Pascual, M.
  • Delgado-Morales, Raul
  • Moran, Sebastian
  • Esteller, Manel, 1968-
  • Sal, M.
  • Boronat Barado, Anna
  • Consiglio, Antonella
  • Addeleccia Bogle, O.
  • Wolwertang, E.
  • Ovchinnikov, D.
  • Álvarez, Iñaki
  • Jaraquemada, Dolores
  • Mezquita Pla, Jovita
  • Oliva, R.
  • Edel, Michael John
When considering the clinical applications of autologous cell replacement therapy of human iPSC‐derived cells there is a clear need to better understand what the immune response will be before we embark on extensive clinical trials to treat or model human disease. We performed a detailed assessment comparing human fibroblast cell lines (termed F1) reprogrammed into human iPSC and subsequently differentiated back to fibroblast cells (termed F2) or other human iPSC‐derived cells including neural stem cells made from either retroviral, episomal or synthetic mRNA cell reprogramming methods. Global proteomic analysis reveals the main differences in signal transduction and immune cell protein expression between F1 and F2 cells, implicating wild type toll like receptor protein 3 (TLR3). Furthermore, global methylome analysis identified an isoform of the human TLR3 gene that is not epigenetically reset correctly upon differentiation to F2 cells resulting in a hypomethylated transcription start site in the TLR3 isoform promoter and overexpression in most human iPSC‐derived cells not seen in normal human tissue. The human TLR3 isoform in human iPSC‐NSC functions to suppress NF‐KB p65 signaling pathway in response to virus (Poly IC), suggesting suppressed immunity of iPSC‐derived cells to viral infection. The sustained wild type TLR3 and TLR3 isoform over expression is central to understanding the altered immunogenicity of human iPSC‐derived cells calling for screening of human iPSC‐derived cells for TLR3 expression levels before applications.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Decapping Protein Edc4 Regulates Dna Repair And Phenocopies Brca1

  • Hernández, Gonzalo
  • Ramírez Bajo, María José
  • Minguillón, Jordi
  • Quiles, Paco
  • Ruiz de Garibay, Gorka
  • Aza-Carmona, Miriam
  • Bogliolo, Massimo
  • Pujol, Roser
  • Prados-Carvajal, Rosario
  • Fernandez, Juana
  • García, Nadia
  • López, Adriá
  • Gutiérrez Enríquez, Sara
  • Díez Gibert, Orland
  • Benitez, Javier
  • Salinas Masdeu, Mònica
  • Teulé-Vega, Àlex
  • Brunet, Joan
  • Radice, Paolo
  • Peterlongo, Paolo
  • Schindler, Detlev
  • Huertas, Pablo
  • Puente, Xose S.
  • Lázaro García, Conxi
  • Pujana Genestar, M. Ángel
  • Surrallés i Calonge, Jordi
BRCA1 is a tumor suppressor that regulates DNA repair by homologous recombination. Germline mutations in BRCA1 are associated with increased risk of breast and ovarian cancer and BRCA1 deficient tumors are exquisitely sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors. Therefore, uncovering additional components of this DNA repair pathway is of extreme importance for further understanding cancer development and therapeutic vulnerabilities. Here, we identify EDC4, a known component of processing-bodies and regulator of mRNA decapping, as a member of the BRCA1-BRIP1-TOPBP1 complex. EDC4 plays a key role in homologous recombination by stimulating end resection at double-strand breaks. EDC4 deficiency leads to genome instability and hypersensitivity to DNA interstrand cross-linking drugs and PARP inhibitors. Lack-of-function mutations in EDC4 were detected in BRCA1/2-mutation-negative breast cancer cases, suggesting a role in breast cancer susceptibility. Collectively, this study recognizes EDC4 with a dual role in decapping and DNA repair whose inactivation phenocopies BRCA1 deficiency.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Decapping protein EDC4 regulates DNA repair and phenocopies BRCA1

  • Hernández, Gonzalo
  • Ramírez, María José
  • Minguillón, Jordi
  • Quiles, Paco
  • Ruiz de Garibay, Gorka
  • Aza Carmona, Miriam
  • Bogliolo, Massimo
  • Pujol, Roser
  • Prados-Carvajal, Rosario
  • Fernández, Juana
  • García, Nadia
  • López, Adrià
  • Gutiérrez-Enríquez, Sara
  • Díez, Orland
  • Benitez, Javier
  • Salinas, Mónica
  • Teulé, Alex
  • Brunet, Joan
  • Radice, Paolo
  • Peterlongo, Paolo
  • Schindler, Detlev
  • Huertas Sánchez, Pablo
  • Puente, Xose S.
  • Lázaro, Conxi
  • Pujana, Miguel Ángel
  • Surrallés, Jordi
BRCA1 is a tumor suppressor that regulates DNA repair by homologous recombination. Germline mutations in BRCA1 are associated with increased risk of breast and ovarian cancer and BRCA1 deficient tumors are exquisitely sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors. Therefore, uncovering additional components of this DNA repair pathway is of extreme importance for further understanding cancer development and therapeutic vulnerabilities. Here, we identify EDC4, a known component of processing-bodies and regulator of mRNA decapping, as a member of the BRCA1-BRIP1-TOPBP1 complex. EDC4 plays a key role in homologous recombination by stimulating end resection at double-strand breaks. EDC4 deficiency leads to genome instability and hypersensitivity to DNA interstrand crosslinking drugs and PARP inhibitors. Lack-of-function mutations in EDC4 were detected in BRCA1/2-mutation-negative breast cancer cases, suggesting a role in breast cancer susceptibility. Collectively, this study recognizes EDC4 with a dual role in decapping and DNA repair whose inactivation phenocopies BRCA1 deficiency, Surrallés laboratory is supported by the ICREA-Academia program, the Marató de TV3 (project 464/C/2012), the Spanish Ministry of Health (projects FANCOSTEM and FANCOLEN), the Spanish Ministry of Economy and Competiveness (projects CB06/07/0023, SAF2012-31881, SAF2013-45836-R and SAF2015-64152-R), the European Commission (EUROFANCOLEN project HEALTH-F5-2012-305421 and P-SPHERE COFUND project), the Fanconi Anemia Research Fund Inc., and the “Fondo Europeo de Desarrollo Regional, una manera de hacer Europa” (FEDER). CIBERER is an initiative of the Instituto de Salud Carlos III, Spain. This work was also supported by grants from the Asociación Española Contra el Cáncer (AECC, Hereditary Cancer group, 2010), the Generalitat de Catalunya (SGR 2014-364 and 2014-338), and the Instituto de Salud Carlos III (PIE13/00022-ONCOPROFILE, CP10/00617, PI10/01422, PI12/02585, PI13/00285, PI15/00854, PI16/00563, PI16/01218, and RTICC RD12/0036/0008). S.G.-E. is funded by a Miguel Servet contract from the Instituto de Salud Carlos III., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Gene therapy restores the transcriptional program of hematopoietic stem cells in Fanconi anemia

  • Lasaga, Miren
  • Río, Paula
  • Vilas-Zornoza, Amaia
  • Planell, Nuria
  • Navarro, Susana
  • Alignani, Diego
  • Fernández-Varas, Beatriz
  • Mouzo, Daniel
  • Zubicaray, Josune
  • Pujol, Roser M.
  • Nicoletti, Eileen
  • Schwartz, Jonathan D.
  • Sevilla Navarro, Julian
  • Ainciburi, Marina
  • UllateAgote, Asier
  • Surrallés, Jordi
  • Perona Abellón, Rosario
  • Sastre, Leandro
  • Prosper, Felipe
  • Gómez-Cabrero, David
  • Bueren, Juan
Clinical trials have shown that lentiviral-mediated gene therapy can ameliorate bone marrow failure (BMF) in nonconditioned Fanconi anemia (FA) patients resulting from the proliferative advantage of corrected FA hematopoietic stem and progenitor cells (HSPC). However, it is not yet known if gene therapy can revert affected molecular pathways in diseased HSPC. Single-cell RNA sequencing was performed in chimeric populations of corrected and uncorrected HSPC co-existing in the BM of gene therapy-treated FA patients. Our study demonstrates that gene therapy reverts the transcriptional signature of FA HSPC, which then resemble the transcriptional program of healthy donor HSPC. This includes a down-regulated expression of TGF-β and p21, typically up-regulated in FA HSPC, and upregulation of DNA damage response and telomere maintenance pathways. Our results show for the first time the potential of gene therapy to rescue defects in the HSPC transcriptional program from patients with inherited diseases; in this case, in FA characterized by BMF and cancer predisposition., This work was supported by grants from the European Commission’s Seventh Framework Program (HEALTH-F5-2012-305421) to the EUROFANCOLEN Consortium (to JB and JSe); from Ministerio de Ciencia, Innovación y Universidades and Fondo Europeo de Desarrollo Regional (RTI2018-097125-B-I00 and PID2021-125077OB-C21, to PR and SN); from Gobierno de Navarra, Departamento de Desarrollo Económico y Empresarial (AGATA 0011-1411-2020-000010); from Instituto de Salud Carlos III (ISCIII) and co-financed by FEDER CIBERONC (CB16/12/00489 and CB16/12/00225); Redes de Investigación Cooperativa (TERCEL RD16/0011/0005); “Instituto de Salud Carlos III (ISCIII)/Red Espanola de Terapias Avanzadas RICORS/TERAV” (RD21/0017/0027), supported by European Union-NextGenerationEU and from Consejería de Educación, Juventud y Deporte de la Comunidad de Madrid (AvanCell Project; B2017/BMD3692); from Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III, Spain, grant n. PI20/0335 and co-funded by European Regional Development (FEDER) funds. MA was supported by a PhD Fellowship from the Ministerio de Ciencia, Innovación y Universidades (FPU18/05488). CIBERER and CIBERONC are initiatives of the Instituto de Salud Carlos III and Fondo Europeo de Desarrollo Regional., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Global proteomic and methylome analysis in human induced pluripotent stem cells reveals overexpression of a human TLR3 affecting proper innate immune response signaling

  • Requena Osete, Jordi
  • Álvarez Palomo, Ana Belén
  • Codina Pascual, M.
  • Delgado-Morales, Raul
  • Moran, Sebastian
  • Esteller, Manel
  • Sal, M.
  • Boronat Barado, Anna
  • Consiglio, Antonella
  • Addeleccia Bogle, O.
  • Wolwertang, E.
  • Ovchinnikov, D.
  • Álvarez, Iñaki
  • Jaraquemada, Dolores
  • Mezquita Pla, Jovita
  • Oliva, R.
  • Edel, Michael John
When considering the clinical applications of autologous cell replacement therapy of human iPSC‐derived cells there is a clear need to better understand what the immune response will be before we embark on extensive clinical trials to treat or model human disease. We performed a detailed assessment comparing human fibroblast cell lines (termed F1) reprogrammed into human iPSC and subsequently differentiated back to fibroblast cells (termed F2) or other human iPSC‐derived cells including neural stem cells made from either retroviral, episomal or synthetic mRNA cell reprogramming methods. Global proteomic analysis reveals the main differences in signal transduction and immune cell protein expression between F1 and F2 cells, implicating wild type toll like receptor protein 3 (TLR3). Furthermore, global methylome analysis identified an isoform of the human TLR3 gene that is not epigenetically reset correctly upon differentiation to F2 cells resulting in a hypomethylated transcription start site in the TLR3 isoform promoter and overexpression in most human iPSC‐derived cells not seen in normal human tissue. The human TLR3 isoform in human iPSC‐NSC functions to suppress NF‐KB p65 signaling pathway in response to virus (Poly IC), suggesting suppressed immunity of iPSC‐derived cells to viral infection. The sustained wild type TLR3 and TLR3 isoform over expression is central to understanding the altered immunogenicity of human iPSC‐derived cells calling for screening of human iPSC‐derived cells for TLR3 expression levels before applications.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Decapping Protein Edc4 Regulates Dna Repair And Phenocopies Brca1

  • Hernández, Gonzalo
  • Ramírez Bajo, María José
  • Minguillón, Jordi
  • Quiles, Paco
  • Ruiz de Garibay, Gorka
  • Aza-Carmona, Miriam
  • Bogliolo, Massimo
  • Pujol, Roser
  • Prados-Carvajal, Rosario
  • Fernandez, Juana
  • Garcia, Nadia
  • López, Adriá
  • Gutiérrez Enríquez, Sara
  • Díez Gibert, Orland
  • Benitez, Javier
  • Salinas Masdeu, Mònica
  • Teulé-Vega, Àlex
  • Brunet, Joan
  • Radice, Paolo
  • Peterlongo, Paolo
  • Schindler, Detlev
  • Huertas, Pablo
  • Puente, Xose S.
  • Lázaro García, Conxi
  • Pujana Genestar, M. Ángel
  • Surrallés i Calonge, Jordi
BRCA1 is a tumor suppressor that regulates DNA repair by homologous recombination. Germline mutations in BRCA1 are associated with increased risk of breast and ovarian cancer and BRCA1 deficient tumors are exquisitely sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors. Therefore, uncovering additional components of this DNA repair pathway is of extreme importance for further understanding cancer development and therapeutic vulnerabilities. Here, we identify EDC4, a known component of processing-bodies and regulator of mRNA decapping, as a member of the BRCA1-BRIP1-TOPBP1 complex. EDC4 plays a key role in homologous recombination by stimulating end resection at double-strand breaks. EDC4 deficiency leads to genome instability and hypersensitivity to DNA interstrand cross-linking drugs and PARP inhibitors. Lack-of-function mutations in EDC4 were detected in BRCA1/2-mutation-negative breast cancer cases, suggesting a role in breast cancer susceptibility. Collectively, this study recognizes EDC4 with a dual role in decapping and DNA repair whose inactivation phenocopies BRCA1 deficiency.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

  • Figlioli, Gisella
  • Catucci, Irene
  • Caleca, Laura
  • Lasheras, Sandra Viz
  • Pujol, Roser
  • Balmaña Gelpí, Judith
  • Diez Gibert, Orland
  • Bogliolo, Massimo
Càncer de mama; Genètica del càncer, Cáncer de mama; Genética del cáncer, Breast cancer; Cancer genetics, Breast cancer is a common disease partially caused by genetic risk factors. Germline pathogenic variants in DNA repair genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 are associated with breast cancer risk. FANCM, which encodes for a DNA translocase, has been proposed as a breast cancer predisposition gene, with greater effects for the ER-negative and triple-negative breast cancer (TNBC) subtypes. We tested the three recurrent protein-truncating variants FANCM:p.Arg658*, p.Gln1701*, and p.Arg1931* for association with breast cancer risk in 67,112 cases, 53,766 controls, and 26,662 carriers of pathogenic variants of BRCA1 or BRCA2. These three variants were also studied functionally by measuring survival and chromosome fragility in FANCM -/- patient-derived immortalized fibroblasts treated with diepoxybutane or olaparib. We observed that FANCM:p.Arg658* was associated with increased risk of ER-negative disease and TNBC (OR = 2.44, P = 0.034 and OR = 3.79; P = 0.009, respectively). In a country-restricted analysis, we confirmed the associations detected for FANCM:p.Arg658* and found that also FANCM:p.Arg1931* was associated with ER-negative breast cancer risk (OR = 1.96; P = 0.006). The functional results indicated that all three variants were deleterious affecting cell survival and chromosome stability with FANCM:p.Arg658* causing more severe phenotypes. In conclusion, we confirmed that the two rare FANCM deleterious variants p.Arg658* and p.Arg1931* are risk factors for ER-negative and TNBC subtypes. Overall our data suggest that the effect of truncating variants on breast cancer risk may depend on their position in the gene. Cell sensitivity to olaparib exposure, identifies a possible therapeutic option to treat FANCM-associated tumors., Peterlongo laboratory is supported by Associazione Italiana Ricerca sul Cancro (AIRC; IG2015 no.16732) to P. Peterlongo and by a fellowship from Fondazione Umberto Veronesi to G. Figlioli. Surrallés laboratory is supported by the ICREA-Academia program, the Spanish Ministry of Health (projects FANCOSTEM and FANCOLEN), the Spanish Ministry of Economy and Competiveness (projects CB06/07/0023 and RTI2018-098419-B-I00), the European Commission (EUROFANCOLEN project HEALTH-F5-2012-305421 and P-SPHERE COFUND project), the Fanconi Anemia Research Fund Inc, and the “Fondo Europeo de Desarrollo Regional, una manera de hacer Europa” (FEDER). CIBERER is an initiative of the Instituto de Salud Carlos III, Spain.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Targeted gene therapy and cell reprogramming in Fanconi anemia

  • Río, Paula
  • Baños, Rocío
  • Lombardo, Angelo
  • Quintana-Bustamante, Oscar|||0000-0002-6869-7006
  • Alvarez, Lara
  • Garate, Zita
  • Genovese, Pietro
  • Almarza, Elena
  • Valeri, Antonio
  • Díez, Begoña
  • Navarro Ordóñez, Susana|||0000-0002-0764-5384
  • Torres, Yaima
  • Trujillo, Juan P.
  • Murillas, Rodolfo
  • Segovia, Jose C.|||0000-0003-4101-6124
  • Samper, Enrique
  • Surralles, Jordi|||0000-0002-4041-7519
  • Gregory, Philip D.
  • Holmes, Michael C.
  • Naldini, Luigi
  • Bueren, Juan|||0000-0002-3228-7013
Gene targeting is progressively becoming a realistic therapeutic alternative in clinics. It is unknown, however, whether this technology will be suitable for the treatment of DNA repair deficiency syndromes such as Fanconi anemia (FA), with defects in homology-directed DNA repair. In this study, we used zinc finger nucleases and integrase-defective lentiviral vectors to demonstrate for the first time that FANCA can be efficiently and specifically targeted into the AAVS1 safe harbor locus in fibroblasts from FA-A patients. Strikingly, up to 40% of FA fibroblasts showed gene targeting 42 days after gene editing. Given the low number of hematopoietic precursors in the bone marrow of FA patients, gene-edited FA fibroblasts were then reprogrammed and re-differentiated toward the hematopoietic lineage. Analyses of gene-edited FA-iPSCs confirmed the specific integration of FANCA in the AAVS1 locus in all tested clones. Moreover, the hematopoietic differentiation of these iPSCs efficiently generated disease-free hematopoietic progenitors. Taken together, our results demonstrate for the first time the feasibility of correcting the phenotype of a DNA repair deficiency syndrome using gene-targeting and cell reprogramming strategies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Individuals with FANCM biallelic mutations do no develop Fanconi anemia, but show risk for breast cancer, chemotherapy sensitivity toxicity and may display chromosome fragility

  • Catucci, Irene
  • Osorio, Ana|||0000-0001-8124-3984
  • Arver, Brita
  • Neidhardt, Guido
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Zanardi, Federica
  • Riboni, Mirko
  • Minardi, Simone
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Azzollini, Jacopo
  • Peissel, Bernard|||0000-0001-9233-3571
  • Manoukian, Siranoush
  • Vecchi, De, Giovanna
  • Casola, Stefano
  • Hauke, Jan|||0000-0001-8236-4075
  • Richters, Lisa
  • Rhiem, Kerstin
  • Schmutzler, Rita K.
  • Wallander, Karin
  • Törngren, Therese
  • Borg, Åke
  • Radice, Paolo|||0000-0001-6298-4111
  • Surralles, Jordi|||0000-0002-4041-7519
  • Hahnen, Eric|||0000-0002-1152-8367
  • Ehrencrona, Hans|||0000-0002-5589-3622
  • Kvist, Anders
  • Benitez, Javier|||0000-0002-0923-7202
  • Peterlongo, Paolo|||0000-0001-6951-6855
PurposeMonoallelic germ-line mutations in the BRCA1/FANCS, BRCA2/FANCD1 and PALB2/FANCN genes confer high risk of breast cancer. Biallelic mutations in these genes cause Fanconi anemia (FA), characterized by malformations, bone marrow failure, chromosome fragility, and cancer predisposition (BRCA2/FANCD1 and PALB2/FANCN), or an FA-like disease presenting a phenotype similar to FA but without bone marrow failure (BRCA1/FANCS). FANCM monoallelic mutations have been reported as moderate risk factors for breast cancer, but there are no reports of any clinical phenotype observed in carriers of biallelic mutations.MethodsBreast cancer probands were subjected to mutation analysis by sequencing gene panels or testing DNA damage response genes.ResultsFive cases homozygous for FANCM loss-of-function mutations were identified. They show a heterogeneous phenotype including cancer predisposition, toxicity to chemotherapy, early menopause, and possibly chromosome fragility. Phenotype severity might correlate with mutation position in the gene.ConclusionOur data indicate that biallelic FANCM mutations do not cause classical FA, providing proof that FANCM is not a canonical FA gene. Moreover, our observations support previous findings suggesting that FANCM is a breast cancer-predisposing gene. Mutation testing of FANCM might be considered for individuals with the above-described clinical features.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Decapping protein EDC4 regulates DNA repair and phenocopies BRCA1

  • Hernández Viedma, Gonzalo|||0000-0002-3048-9607
  • Ramírez de Haro, Ma. José|||0000-0003-1417-7731
  • Minguillón Pedreño, Jordi|||0000-0003-2124-8294
  • Quiles, Francisco
  • Ruiz de Garibay, G.
  • Aza-Carmona, Miriam|||0000-0003-4448-9541
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Prados-Carvajal, Rosario
  • Fernández-Rodríguez, Juana
  • García, Nadia
  • López, Adrià
  • Gutiérrez-Enríquez, Sara|||0000-0002-1711-6101
  • Diez, Orland|||0000-0001-7339-0570
  • Benitez, Javier|||0000-0002-0923-7202
  • Salinas, Monica
  • Teule, Alex|||0000-0003-0028-7200
  • Brunet, Joan|||0000-0003-1945-3512
  • Radice, Paolo|||0000-0001-6298-4111
  • Peterlongo, Paolo|||0000-0001-6951-6855
  • Schindler, Detlev
  • Huertas, Pablo
  • Puente, Xose P.
  • Lázaro, Coxi
  • Pujana, Miguel Angel|||0000-0003-3222-4044
  • Surralles, Jordi|||0000-0002-4041-7519
BRCA1 is a tumor suppressor that regulates DNA repair by homologous recombination. Germline mutations in BRCA1 are associated with increased risk of breast and ovarian cancer and BRCA1 deficient tumors are exquisitely sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors. Therefore, uncovering additional components of this DNA repair pathway is of extreme importance for further understanding cancer development and therapeutic vulnerabilities. Here, we identify EDC4, a known component of processing-bodies and regulator of mRNA decapping, as a member of the BRCA1-BRIP1-TOPBP1 complex. EDC4 plays a key role in homologous recombination by stimulating end resection at double-strand breaks. EDC4 deficiency leads to genome instability and hypersensitivity to DNA interstrand cross-linking drugs and PARP inhibitors. Lack-of-function mutations in EDC4 were detected in BRCA1/2-mutation-negative breast cancer cases, suggesting a role in breast cancer susceptibility. Collectively, this study recognizes EDC4 with a dual role in decapping and DNA repair whose inactivation phenocopies BRCA1 deficiency.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

From exome analysis in idiopathic azoospermia to the identification of a high-risk subgroup for occult Fanconi anemia

  • Krausz, Csilla|||0000-0001-6748-8918
  • Riera-Escamilla, Antoni|||0000-0002-4485-3094
  • Chianese, Chiara|||0000-0002-8952-0584
  • Moreno-Mendoza, Daniel
  • Ars, Elisabet|||0000-0002-4118-4358
  • Rajmil Marquenson, Osvlado|||0000-0003-1987-9206
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Blanco Guillermo, Ignacio|||0000-0002-7414-7481
  • Rodríguez, Inés
  • Badell Serra, Isabel|||0000-0001-6546-2175
  • Ruiz-Castañé, Eduardo|||0000-0002-7469-4610
  • Surralles, Jordi|||0000-0002-4041-7519
Purpose: in about 10% of patients affected by Fanconi anemia (FA) the diagnosis is delayed until adulthood, and the presenting symptom in these "occult" FA cases is often a solid cancer and cancer treatment-related toxicity. Highly predictive clinical parameter(s) for diagnosing such an adult-onset cases are missing. - Methods: (1) Exome sequencing (ES), (2) Sanger sequencing of FANCA, (3) diepoxybutane (DEB)-induced chromosome breakage test. - Results: ES identified a pathogenic homozygous FANCA variant in a patient affected by Sertoli cell-only syndrome (SCOS) and in his azoospermic brother. Although they had no overt anemia, chromosomal breakage test revealed a reverse somatic mosaicism in the former and a typical FA picture in the latter. In 27 selected SCOS cases, 1 additional patient showing compound heterozygous pathogenic FANCA variants was identified with positive chromosomal breakage test. - Conclusion: we report an extraordinarily high frequency of FA in a specific subgroup of azoospermic patients (7.1%). The screening for FANCA pathogenic variants in such patients has the potential to identify undiagnosed FA before the appearance of other severe clinical manifestations of the disease. The definition of this high-risk group for "occult" FA, based on specific testis phenotype with mild/borderline hematological alterations, is of unforeseen clinical relevance.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Functional comparison of XPF missense mutations associated to multiple DNA repair disorders

  • Marín, Maria
  • Ramírez de Haro, Ma. José|||0000-0003-1417-7731
  • Aza-Carmona, Miriam|||0000-0003-4448-9541
  • Jia, Nan
  • Ogi, Tomoo
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Surralles, Jordi|||0000-0002-4041-7519
XPF endonuclease is one of the most important DNA repair proteins. Encoded by XPF/ERCC4, XPF provides the enzymatic activity of XPF-ERCC1 heterodimer, an endonuclease that incises at the 5' side of various DNA lesions. XPF is essential for nucleotide excision repair (NER) and interstrand crosslink repair (ICLR). XPF/ERCC4 mutations are associated with several human diseases: Xeroderma Pigmentosum (XP), Segmental Progeria (XFE), Fanconi Anemia (FA), Cockayne Syndrome (CS), and XP/CS combined disease (XPCSCD). Most affected individuals are compound heterozygotes for XPF/ERCC4 mutations complicating the identification of genotype/phenotype correlations. We report a detailed overview of NER and ICLR functional studies in human XPF-KO (knock-out) isogenic cells expressing six disease-specific pathogenic XPF amino acid substitution mutations. Ultraviolet (UV) sensitivity and unscheduled DNA synthesis (UDS) assays provide the most reliable information to discern mutations associated with ICLR impairment from mutations related to NER deficiency, whereas recovery of RNA synthesis (RRS) assays results hint to a possible role of XPF in resolving R-loops. Our functional studies demonstrate that a defined cellular phenotype cannot be easily correlated to each XPF mutation. Substituted positions along XPF sequences are not predictive of cellular phenotype nor reflect a particular disease. Therefore, in addition to mutation type, allelic interactions, protein stability and intracellular distribution of mutant proteins may also contribute to alter DNA repair pathways balance leading to clinically distinct disorders.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Global proteomic and methylome analysis in human induced pluripotent stem cells reveals overexpression of a human TLR3 affecting proper innate immune response signaling

  • Requena, Jordi
  • Álvarez Palomo, Belén|||0000-0002-3894-044X
  • Codina, Montserrat|||0000-0001-5591-8095
  • Delgado Morales, Raúl|||0000-0002-8538-4087
  • Moran, S.|||0000-0003-4192-8983
  • Esteller, M.|||0000-0003-4490-6093
  • Sal, Martí
  • Juan, Manel|||0000-0002-3064-1648
  • Boronat Barado, Anna
  • Consiglio, Antonella
  • Bogle, Orleigh Addeleccia
  • Wolvetang, Ernst
  • Ovchinnikov, Dmitry
  • Álvarez Pérez, Iñaki|||0000-0001-9484-0868
  • Jaraquemada, Dolores|||0000-0003-3328-740X
  • Mezquita Pla, Jovita
  • Oliva Virgili, Rafael|||0000-0003-4876-2410
  • Edel, Michael J.|||0000-0002-5619-8680
When considering the clinical applications of autologous cell replacement therapy of human induced pluripotent stem cells (iPSC)-derived cells, there is a clear need to better understand what the immune response will be before we embark on extensive clinical trials to treat or model human disease. We performed a detailed assessment comparing human fibroblast cell lines (termed F1) reprogrammed into human iPSC and subsequently differentiated back to fibroblast cells (termed F2) or other human iPSC-derived cells including neural stem cells (NSC) made from either retroviral, episomal, or synthetic mRNA cell reprogramming methods. Global proteomic analysis reveals the main differences in signal transduction and immune cell protein expression between F1 and F2 cells, implicating wild type (WT) toll like receptor protein 3 (TLR3). Furthermore, global methylome analysis identified an isoform of the human TLR3 gene that is not epigenetically reset correctly upon differentiation to F2 cells resulting in a hypomethylated transcription start site in the TLR3 isoform promoter and overexpression in most human iPSC-derived cells not seen in normal human tissue. The human TLR3 isoform in human iPSC-NSC functions to suppress NF-KB p65 signaling pathway in response to virus (Poly IC), suggesting suppressed immunity of iPSC-derived cells to viral infection. The sustained WT TLR3 and TLR3 isoform overexpression is central to understanding the altered immunogenicity of human iPSC-derived cells calling for screening of human iPSC-derived cells for TLR3 expression levels before applications. Stem Cells 2019;37:476-488.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The FANCM :p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

  • Figlioli, Gisella|||0000-0002-0740-1363
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Catucci, Irene
  • Caleca, Laura|||0000-0002-3381-7493
  • Viz Lasheras, Sandra|||0000-0001-5873-5104
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Kiiski, Johanna I.
  • Muranen, Taru A.|||0000-0002-5895-1808
  • Barnes, Daniel R.|||0000-0002-3781-7570
  • Dennis, Joe|||0000-0003-4591-1214
  • Michailidou, Kyriaki
  • Bolla, Manjeet K.|||0000-0002-4351-9326
  • Leslie, Goska|||0000-0001-5756-6222
  • Aalfs, Cora M.
  • Adank, Muriel A.
  • Adlard, Julian|||0000-0002-1693-0435
  • Agata, Simona
  • Cadoo, Karen
  • Agnarsson, Bjarni A.
  • Ahearn, Thomas
  • Aittomäki, Kristiina
  • Ambrosone, Christine B.
  • Andrews, Lesley
  • Anton-Culver, Hoda
  • Antonenkova, Natalia N.
  • Arndt, Volker|||0000-0001-9320-8684
  • Arnold, Norbert
  • Aronson, Kristan J.
  • Arun, Banu K.
  • Asseryanis, Ella
  • Auber, Bernd|||0000-0003-1880-291X
  • Auvinen, Päivi
  • Azzollini, Jacopo
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Barkardottir, Rosa B.
  • Barrowdale, Daniel|||0000-0003-1661-3939
  • Barwell, Julian
  • Beane-Freeman, Laura
  • Beauparlant, Charles Joly
  • Beckmann, Matthias W.
  • Behrens, Sabine
  • Benitez, Javier|||0000-0002-0923-7202
  • Berger, Raanan
  • Bermisheva, Marina
  • Blanco, Amie M.
  • Blomqvist, Carl
  • Bogdanova, Natalia V.
  • Bojesen, Anders|||0000-0003-4289-8595
  • Bojesen, Stig E.
  • Bonanni, Bernardo|||0000-0003-3589-2128
  • Borg, Åke
  • Brady, Angela F.
  • Brauch, Hiltrud|||0000-0001-7531-2736
  • Brenner, Hermann
  • Brüning, Thomas
  • Burwinkel, Barbara
  • Buys, Saundra|||0000-0003-4120-5697
  • Caldes, Trinidad
  • Caliebe, Almuth
  • Caligo, Maria|||0000-0003-0589-1829
  • Campa, Daniele|||0000-0003-3220-9944
  • Campbell, Ian|||0000-0002-7773-4155
  • Canzian, Federico|||0000-0002-4261-4583
  • Castelao, Jose E.
  • Chang-Claude, Jenny
  • Chanock, Stephen|||0000-0002-2324-3393
  • Claes, Kathleen|||0000-0003-0841-7372
  • Clarke, Christine L.
  • Collavoli, Anita
  • Conner, Thomas A.
  • Cox, David G.
  • Cybulski, Cezary|||0000-0002-2819-3057
  • Czene, Kamila
  • Daly, Mary B.
  • Hoya, Miguel de la|||0000-0002-8113-1410
  • Devilee, Peter|||0000-0002-8023-2009
  • Diez, Orland|||0000-0001-7339-0570
  • Ding, Yuan Chun
  • Dite, Gillian S.
  • Ditsch, Nina
  • Domchek, Susan M.|||0000-0002-5914-7272
  • Dorfling, Cecilia M.
  • dos-Santos-Silva, Isabel
  • Durda, Katarzyna
  • Dwek, Miriam
  • Eccles, Diana M.|||0000-0002-9935-3169
  • Ekici, Arif B.
  • Eliassen, A. Heather
  • Ellberg, Carolina
  • Eriksson, Mikael
  • Evans, Gareth|||0000-0002-8482-5784
  • Fasching, Peter A.
  • Figueroa, Jonine
  • Flyger, Henrik
  • Foulkes, William|||0000-0001-7427-4651
  • Friebel, Tara M.
  • Friedman, Eitan|||0000-0002-6745-1733
  • Gabrielson, Marike
  • Gaddam, Pragna
  • Gago-Dominguez, Manuela
  • Gao, Chi
  • Gapstur, Susan M.
  • Garber, Judy
  • García-Closas, Montserrat
  • García-Sáenz, José A.|||0000-0001-6880-0301
  • Gaudet, Mia M.
  • Gayther, Simon A.|||0000-0001-7937-5443
  • Giles, Graham G.
  • Glendon, Gord
  • Godwin, Andrew K.|||0000-0002-3987-9580
  • Goldberg, Mark S.
  • Goldgar, David E.
  • Guénel, Pascal
  • Gutierrez-Barrera, Angelica M.
  • Haeberle, Lothar
  • Haiman, Christopher A.
  • Håkansson, Niclas
  • Hall, Per
  • Hamann, Ute|||0000-0001-6705-7624
  • Harrington, Patricia A.
  • Hein, Alexander
  • Heyworth, Jane
  • Hillemanns, Peter
  • Hollestelle, Antoinette
  • Hopper, John L.
  • Hosgood, H. Dean
  • Howell, Anthony
  • Hu, Chunling
  • Hulick, Peter J.
  • Hunter, David J.
  • Imyanitov, Evgeny N.
  • Isaacs, Claudine|||0000-0002-9646-1260
  • Jakimovska, Milena|||0000-0002-1506-0669
  • Jakubowska, Anna|||0000-0002-5650-0501
  • James, Paul|||0000-0002-4361-4657
  • Janavicius, Ramunas
  • Janni, Wolfgang
  • John, Esther M.
  • Jones, Michael E.
  • Jung, Audrey
  • Kaaks, Rudolf
  • Karlan, Beth Y.|||0000-0002-9451-2933
  • Khusnutdinova, Elza
  • Kitahara, Cari M.
  • Konstantopoulou, Irene|||0000-0002-0470-0309
  • Koutros, Stella
  • Kraft, Peter
  • Lambrechts, Diether
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Le Marchand, Loic
  • Lester, Jenny
  • Lesueur, Fabienne|||0000-0001-7404-4549
  • Lilyquist, Jenna
  • Loud, Jennifer T.
  • Lu, Karen H.
  • Luben, Robert N.
  • Lubinski, Jan|||0000-0003-2931-3003
  • Mannermaa, Arto
  • Manoochehri, Mehdi
  • Manoukian, Siranoush
  • Margolin, Sara
  • Martens, John W. M.
  • Maurer, Tabea
  • Mavroudis, Dimitrios
  • Mebirouk, Noura
  • Meindl, Alfons
  • Menon, Usha|||0000-0003-3708-1732
  • Miller, Austin|||0000-0001-9739-8462
  • Montagna, Marco
  • Nathanson, Katherine L.|||0000-0002-6740-0901
  • Neuhausen, Susan L.|||0000-0001-5053-0390
  • Newman, William G.
  • Nguyen-Dumont, Tu
  • Nielsen, Finn Cilius
  • Nielsen, Sarah
  • Nikitina-Zake, Liene
  • Offit, Kenneth
  • Olah, Edith
  • Olopade, Olufunmilayo I.|||0000-0002-9936-1599
  • Olshan, Andrew F.
  • Olson, Janet E.
  • Olsson, Håkan
  • Osorio, Ana|||0000-0001-8124-3984
  • Ottini, Laura
  • Peissel, Bernard|||0000-0001-9233-3571
  • Peixoto, Ana
  • Peto, Julian|||0000-0002-1685-8912
  • Plaseska-Karanfilska, Dijana
  • Pocza, Timea
  • Presneau, Nadege
  • Pujana, Miguel Angel|||0000-0003-3222-4044
  • Punie, Kevin|||0000-0002-1162-7963
  • Rack, Brigitte
  • Rantala, Johanna
  • Rashid, Muhammad U.|||0000-0002-7684-3122
  • Rau-Murthy, Rohini
  • Rennert, Gad|||0000-0002-8512-068X
  • Lejbkowicz, Flavio|||0000-0001-5718-0418
  • Rhenius, Valerie
  • Romero, Atocha|||0000-0002-1634-7397
  • Rookus, Matti A.
  • Ross, Eric A.
  • Rossing, Maria
  • Rudaitis, Vilius
  • Ruebner, Matthias
  • Saloustros, Emmanouil|||0000-0002-0485-0120
  • Sanden, Kristin
  • Santamariña, Marta
  • Scheuner, Maren T.
  • Schmutzler, Rita K.
  • Schneider, Michael
  • Scott, Christopher|||0000-0003-1340-0647
  • Senter, Leigha
  • Shah, Mitul
  • Sharma, Priyanka
  • Shu, Xiao-Ou
  • Simard, Jacques|||0000-0001-6906-3390
  • Singer, Christian F.
  • Sohn, Christof
  • Soucy, Penny
  • Southey, Melissa C.|||0000-0002-6313-9005
  • Spinelli, John J.
  • Steele, Linda
  • Stoppa-Lyonnet, Dominique
  • Tapper, William J.
  • Teixeira, Manuel R.|||0000-0002-4896-5982
  • Terry, Mary Beth
  • Thomassen, Mads
  • Thompson, Jennifer
  • Thull, Darcy L.
  • Tischkowitz, Marc
  • Tollenaar, Rob A. E. M.
  • Torres, Diana
  • Troester, Melissa A.
  • Truong, Thérèse
  • Tung, Nadine
  • Untch, Michael
  • Vachon, Celine M.
  • van Rensburg, Elizabeth J.|||0000-0003-2077-230X
  • van Veen, Elke M.
  • Vega, Ana|||0000-0002-7416-5137
  • Viel, Alessandra|||0000-0003-2804-0840
  • Wappenschmidt, Barbara
  • Weitzel, Jeffrey N.
  • Wendt, Camilla
  • Wieme, Greet|||0000-0003-2718-5300
  • Wolk, Alicja
  • Yang, Xiaohong R.
  • Zheng, Wei|||0000-0003-1226-070X
  • Ziogas, Argyrios|||0000-0003-4529-3727
  • Zorn, Kristin K.
  • Dunning, Alison M.
  • Lush, Michael
  • Wang, Qin
  • McGuffog, Lesley|||0000-0003-1237-0546
  • Parsons, Michael T.
  • Pharoah, Paul D.P.|||0000-0001-8494-732X
  • Fostira, Florentia
  • Toland, Amanda Ewart|||0000-0002-0271-1792
  • Andrulis, Irene L.|||0000-0002-4226-6435
  • Ramus, Susan J.|||0000-0003-0005-7798
  • Swerdlow, Anthony J.
  • Greene, Mark H.|||0000-0003-1852-9239
  • Chung, Wendy
  • Milne, Roger L.|||0000-0001-5764-7268
  • Chenevix-Trench, Georgia
  • Dörk, Thilo|||0000-0002-9458-0282
  • Schmidt, Marjanka K.|||0000-0002-2228-429X
  • Easton, Douglas F.|||0000-0003-2444-3247
  • Radice, Paolo|||0000-0001-6298-4111
  • Hahnen, Eric|||0000-0002-1152-8367
  • Antoniou, Antonis C.
  • Couch, Fergus J.
  • Nevanlinna, Heli|||0000-0002-0916-2976
  • Surralles, Jordi|||0000-0002-4041-7519
  • Peterlongo, Paolo|||0000-0001-6951-6855
Breast cancer is a common disease partially caused by genetic risk factors. Germline pathogenic variants in DNA repair genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 are associated with breast cancer risk. FANCM, which encodes for a DNA translocase, has been proposed as a breast cancer predisposition gene, with greater effects for the ER-negative and triple-negative breast cancer (TNBC) subtypes. We tested the three recurrent protein-truncating variants FANCM :p.Arg658*, p.Gln1701*, and p.Arg1931* for association with breast cancer risk in 67,112 cases, 53,766 controls, and 26,662 carriers of pathogenic variants of BRCA1 or BRCA2. These three variants were also studied functionally by measuring survival and chromosome fragility in FANCM -/- patient-derived immortalized fibroblasts treated with diepoxybutane or olaparib. We observed that FANCM :p.Arg658* was associated with increased risk of ER-negative disease and TNBC (OR = 2.44, P = 0.034 and OR = 3.79; P = 0.009, respectively). In a country-restricted analysis, we confirmed the associations detected for FANCM :p.Arg658* and found that also FANCM :p.Arg1931* was associated with ER-negative breast cancer risk (OR = 1.96; P = 0.006). The functional results indicated that all three variants were deleterious affecting cell survival and chromosome stability with FANCM :p.Arg658* causing more severe phenotypes. In conclusion, we confirmed that the two rare FANCM deleterious variants p.Arg658* and p.Arg1931* are risk factors for ER-negative and TNBC subtypes. Overall our data suggest that the effect of truncating variants on breast cancer risk may depend on their position in the gene. Cell sensitivity to olaparib exposure, identifies a possible therapeutic option to treat FANCM -associated tumors.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Improved collection of hematopoietic stem cells and progenitors from Fanconi anemia patients for gene therapy purposes

  • Sevilla, Julián|||0000-0002-6852-1860
  • Navarro Ordóñez, Susana|||0000-0002-0764-5384
  • Río, Paula
  • Sánchez Domínguez, Rebeca
  • Zubicaray, Josune|||0000-0003-4115-9598
  • Gálvez, Eva
  • Merino, Eva
  • Sebastián, Elena
  • Azqueta, Carmen
  • Casado, José A.|||0000-0003-2479-1508
  • Segovia, Jose C.|||0000-0003-4101-6124
  • Alberquilla, Omaira|||0000-0002-0301-8340
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Román-Rodríguez, Francisco J.
  • Giménez, Yari|||0000-0002-8936-0007
  • Larcher, Lise
  • Salgado Sánchez, Rocío Nieves|||0000-0003-1678-8982
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Hladun, Raquel|||0000-0002-3191-1750
  • Castillo, Ana
  • Soulier, Jean|||0000-0002-8734-5356
  • Querol, Sergi|||0000-0002-1105-8633
  • Fernández, Jesús
  • Schwartz, Jonathan|||0000-0002-2211-4151
  • García de Andoín, Nagore|||0000-0003-2660-2600
  • López, Ricardo
  • Català, Albert|||0000-0003-0133-1752
  • Surralles, Jordi|||0000-0002-4041-7519
  • Díaz de Heredia, Cristina|||0000-0001-8086-296X
  • Bueren, Juan|||0000-0002-3228-7013
Difficulties in the collection of hematopoietic stem and progenitor cells (HSPCs) from Fanconi anemia (FA) patients have limited the gene therapy in this disease. We have investigated (, NCT02931071) the safety and efficacy of filgrastim and plerixafor for mobilization of HSPCs and collection by leukapheresis in FA patients. Nine of eleven enrolled patients mobilized beyond the threshold level of 5 CD34 + cells/μL required to initiate apheresis. A median of 21.8 CD34 + cells/μL was reached at the peak of mobilization. Significantly, the oldest patients (15 and 16 years old) were the only ones who did not reach that threshold. A median of 4.27 million CD34 + cells/kg was collected in 2 or 3 aphereses. These numbers were markedly decreased to 1.1 million CD34 + cells/kg after immunoselection, probably because of weak expression of the CD34 antigen. However, these numbers were sufficient to facilitate the engraftment of corrected HSPCs in non-conditioned patients. No procedure-associated serious adverse events were observed. Mobilization of CD34 + cells correlated with younger age, higher leukocyte counts and hemoglobin values, lower mean corpuscular volume, and higher proportion of CD34 + cells in bone marrow (BM). All these values offer crucial information for the enrollment of FA patients for gene therapy protocols. Mobilization and collection of HSPCs from FA patients with sufficient HSPC reserve is a safe and efficient procedure, incorporating filgrastim and plerixafor as mobilization agents. Adequate HSPC mobilization correlates with younger age, higher leukocyte counts and hemoglobin values, lower mean corpuscular volume, and higher BM CD34 + cell numbers.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

TALEN mediated gene editing in a mouse model of Fanconi anemia

  • Pino-Barrio, Maria José
  • Giménez, Yari|||0000-0002-8936-0007
  • Villanueva, Mariela
  • Hildenbeutel, Marcus
  • Sánchez Domínguez, Rebeca
  • Rodriguez-Perales, Sandra|||0000-0001-7221-3636
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Surralles, Jordi|||0000-0002-4041-7519
  • Río, Paula
  • Cathomen, Toni|||0000-0002-7757-4630
  • Mussolino, Claudio
  • Bueren, Juan|||0000-0002-3228-7013
  • Navarro Ordóñez, Susana|||0000-0002-0764-5384
The promising ability to genetically modify hematopoietic stem and progenitor cells by precise gene editing remains challenging due to their sensitivity to in vitro manipulations and poor efficiencies of homologous recombination. This study represents the first evidence of implementing a gene editing strategy in a murine safe harbor locus site that phenotypically corrects primary cells from a mouse model of Fanconi anemia A. By means of the co-delivery of transcription activator-like effector nucleases and a donor therapeutic FANCA template to the Mbs85 locus, we achieved efficient gene targeting (23%) in mFA-A fibroblasts. This resulted in the phenotypic correction of these cells, as revealed by the reduced sensitivity of these cells to mitomycin C. Moreover, robust evidence of targeted integration was observed in murine wild type and FA-A hematopoietic progenitor cells, reaching mean targeted integration values of 21% and 16% respectively, that were associated with the phenotypic correction of these cells. Overall, our results demonstrate the feasibility of implementing a therapeutic targeted integration strategy into the m Mbs85 locus, ortholog to the well-validated hAAVS1, constituting the first study of gene editing in mHSC with TALEN, that sets the basis for the use of a new safe harbor locus in mice.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clinical consequences of BRCA2 hypomorphism

  • Castells Roca, Laia|||0000-0002-4604-9999
  • Gutiérrez-Enríquez, Sara|||0000-0002-1711-6101
  • Bonache, Sandra|||0000-0002-7395-8143
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Carrasco, Estela|||0000-0003-1964-7675
  • Aza-Carmona, Miriam|||0000-0003-4448-9541
  • Montalban, Gemma|||0000-0002-6958-4759
  • Muñoz-Subirana, N.
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Cruz Zambrano, Cristina|||0000-0002-6474-7504
  • Llop Guevara, Alba|||0000-0002-7913-9472
  • Ramírez de Haro, Ma. José|||0000-0003-1417-7731
  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Lasa, Adriana|||0000-0001-9957-9646
  • Serra, Violeta|||0000-0001-6620-1065
  • Diez, Orland|||0000-0001-7339-0570
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Surralles, Jordi|||0000-0002-4041-7519
The tumor suppressor FANCD1/BRCA2 is crucial for DNA homologous recombination repair (HRR). BRCA2 biallelic pathogenic variants result in a severe form of Fanconi anemia (FA) syndrome, whereas monoallelic pathogenic variants cause mainly hereditary breast and ovarian cancer predisposition. For decades, the co-occurrence in trans with a clearly pathogenic variant led to assume that the other allele was benign. However, here we show a patient with biallelic BRCA2 (c.1813dup and c.7796 A.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Upregulation of NKG2D ligands impairs hematopoietic stem cell function in Fanconi anemia

  • Casado, José A.|||0000-0003-2479-1508
  • Valeri, A.
  • Sánchez Domínguez, Rebeca
  • Vela, Paula
  • Lopez, A.
  • Navarro Ordóñez, Susana|||0000-0002-0764-5384
  • Alberquilla, Omaira|||0000-0002-0301-8340
  • Hanenberg, H.
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Segovia, J. C.
  • Minguillon, J.
  • Surralles, Jordi|||0000-0002-4041-7519
  • De Heredia, C.D.
  • Sevilla, J.
  • Rio, P.
  • Bueren, Juan|||0000-0002-3228-7013
Fanconi anemia (FA) is the most prevalent inherited bone marrow failure (BMF) syndrome. Nevertheless, the pathophysiological mechanisms of BMF in FA have not been fully elucidated. Since FA cells are defective in DNA repair, we hypothesized that FA hematopoietic stem and progenitor cells (HSPCs) might express DNA damage-associated stress molecules such as natural killer group 2 member D ligands (NKG2D-Ls). These ligands could then interact with the activating NKG2D receptor expressed in cytotoxic NK or CD8+ T cells, which may result in progressive HSPC depletion. Our results indeed demonstrated upregulated levels of NKG2D-Ls in cultured FA fibroblasts and T cells, and these levels were further exacerbated by mitomycin C or formaldehyde. Notably, a high proportion of BM CD34+ HSPCs from patients with FA also expressed increased levels of NKG2D-Ls, which correlated inversely with the percentage of CD34+ cells in BM. Remarkably, the reduced clonogenic potential characteristic of FA HSPCs was improved by blocking NKG2D-NKG2D-L interactions. Moreover, the in vivo blockage of these interactions in a BMF FA mouse model ameliorated the anemia in these animals. Our study demonstrates the involvement of NKG2D-NKG2D-L interactions in FA HSPC functionality, suggesting an unexpected role of the immune system in the progressive BMF that is characteristic of FA.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

  • Figlioli, Gisella
  • Catucci, Irene
  • Caleca, Laura
  • Lasheras, Sandra Viz
  • Pujol, Roser
  • Balmaña Gelpí, Judith
  • Diez Gibert, Orland
  • Bogliolo, Massimo
Càncer de mama; Genètica del càncer, Cáncer de mama; Genética del cáncer, Breast cancer; Cancer genetics, Breast cancer is a common disease partially caused by genetic risk factors. Germline pathogenic variants in DNA repair genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 are associated with breast cancer risk. FANCM, which encodes for a DNA translocase, has been proposed as a breast cancer predisposition gene, with greater effects for the ER-negative and triple-negative breast cancer (TNBC) subtypes. We tested the three recurrent protein-truncating variants FANCM:p.Arg658*, p.Gln1701*, and p.Arg1931* for association with breast cancer risk in 67,112 cases, 53,766 controls, and 26,662 carriers of pathogenic variants of BRCA1 or BRCA2. These three variants were also studied functionally by measuring survival and chromosome fragility in FANCM -/- patient-derived immortalized fibroblasts treated with diepoxybutane or olaparib. We observed that FANCM:p.Arg658* was associated with increased risk of ER-negative disease and TNBC (OR = 2.44, P = 0.034 and OR = 3.79; P = 0.009, respectively). In a country-restricted analysis, we confirmed the associations detected for FANCM:p.Arg658* and found that also FANCM:p.Arg1931* was associated with ER-negative breast cancer risk (OR = 1.96; P = 0.006). The functional results indicated that all three variants were deleterious affecting cell survival and chromosome stability with FANCM:p.Arg658* causing more severe phenotypes. In conclusion, we confirmed that the two rare FANCM deleterious variants p.Arg658* and p.Arg1931* are risk factors for ER-negative and TNBC subtypes. Overall our data suggest that the effect of truncating variants on breast cancer risk may depend on their position in the gene. Cell sensitivity to olaparib exposure, identifies a possible therapeutic option to treat FANCM-associated tumors., Peterlongo laboratory is supported by Associazione Italiana Ricerca sul Cancro (AIRC; IG2015 no.16732) to P. Peterlongo and by a fellowship from Fondazione Umberto Veronesi to G. Figlioli. Surrallés laboratory is supported by the ICREA-Academia program, the Spanish Ministry of Health (projects FANCOSTEM and FANCOLEN), the Spanish Ministry of Economy and Competiveness (projects CB06/07/0023 and RTI2018-098419-B-I00), the European Commission (EUROFANCOLEN project HEALTH-F5-2012-305421 and P-SPHERE COFUND project), the Fanconi Anemia Research Fund Inc, and the “Fondo Europeo de Desarrollo Regional, una manera de hacer Europa” (FEDER). CIBERER is an initiative of the Instituto de Salud Carlos III, Spain.